CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML
The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML).
1. Determine the maximum tolerated dose (MTD) of CD8-depleted non-engrafting human leukocyte antigen (HLA) mismatched unrelated donor lymphocyte infusion (NE-DLI) in patients with myeloid malignancies.
2. Estimate the response rate to therapy with CD8-depleted NE-DLI in patients with myelodysplastic syndrome (MDS) who have failed therapy with hypomethylating agents (HMAs) or untreated patients with acute myeloid leukemia (AML) secondary to an antecedent hematologic disease (sAML).
Myelodysplastic Syndrome (MDS) having failed hypomethylating agent (HMA) therapy cohort:
Age 18-79 years, inclusive
Pathologically confirmed MDS or myelodysplastic/myeloproliferative overlap (MDS/MPN)
IPSS-R score intermediate, high or very high
Must have failed therapy with an HMA (defined as lack of response by International Working Group criteria (1) or intolerance of the drug)
Secondary Acute Myeloid Leukemia (sAML) :
Pathologically confirmed AML according to World Health Organization (WHO) criteria
Evidence of an antecedent hematologic disorder (AHD) prior to acute leukemia including a known prior diagnosis of MDS, MPN or MDS/MPN or data suggestive of an AHD such as cytopenias, fibrosis, macrocytic anemia, cellular or dysplasia at or prior to the time of diagnosis. > If available, MDS-defining karyotypes (-7/del(7q), -5/del(5q), del(13q), del(11q), del(12p), t(12p), del(9q), idic(X)(q13), t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p), t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34)) or somatic mutations in multiple genes including p53, TET2, JAK2, CALR, MPL, ASXL1, RUNX1, SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 would also confirm eligibility.
Age 18-79 years, inclusive
May be previously untreated
For both cohorts:
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Deemed eligible to receive cytotoxic chemotherapy
Creatinine clearance (CrCl)>50ml/min
Total bilirubin > Left Ventricular Ejection Fraction > 50%
Willing and able to participate in study assessments
Patients who have had systemic chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Hydroxurea during this period may be given as a bridging therapy to maintain disease stability while awaiting trial treatment. Intrathecal chemotherapy within this time frame is permitted. Intrathecal chemotherapy may be continued during protocol therapy in order to consolidate or maintain a central nervous system (CNS) remission, but not to treat active CNS disease
Acute promyelocytic leukemia, or the presence of t(15;17)
Patients receiving any other investigational agents
Uncontrolled concurrent illness including, but not limited to, ongoing and uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in the fetus. Breastfeeding should be discontinued if the mother is treated. These potential risks may also apply to other agents used in this study
Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow-up
Patients with a poor functional status of ECOG 3-4, or otherwise deemed unfit to tolerate induction chemotherapy.
Patients with blastic transformation of chronic myelogenous leukemia are ineligible
Exposure to a humanized mouse chimeric antibody, as this could sensitize patients to components of the CD8 depletion column that may be present in small amounts in the cell product
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub